The global Phase III VANCE trial of the autologous EBV-targeted T-cell therapy was the largest trial of a solid tumor cell ...

The Missouri hospital system designed its own 13-gene PGx panel, which it runs at its molecular genetics lab and calls the ...

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...

NEW YORK – BeiGene on Wednesday said the European Commission approved the anti-PD-1 monoclonal antibody Tevimbra (tislelizumab) with chemotherapy as a first-line treatment for esophageal squamous cell ...

NEW YORK – Anocca said on Tuesday that it is seeking permission from the European Medicines Agency to begin testing its T-cell receptor (TCR) T-cell therapy ANOC-001 in a Phase I/II trial in advanced ...

Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.

The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.